<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802087</url>
  </required_header>
  <id_info>
    <org_study_id>HC-EG-001</org_study_id>
    <nct_id>NCT00802087</nct_id>
  </id_info>
  <brief_title>Single Dose Pharmacokinetics of Egalet® Hydrocodone</brief_title>
  <official_title>A Single-Centre, Single Dose, Randomized,Open Label, Exploratory, 5-way Crossover Study Evaluating the Pharmakokinetic Profiles of Various Egalet® Hydrocodone Formulations In Healthy Volunteers Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egalet Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Egalet Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the pharmacokinetic profile of different Egalet®
      hydrocodone formulations and compare to a marketed hydrocodone drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcomes:

      Pharmacokinetic parameters and bioequivalence testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the Pharmacokinetics of Egalet® hydrocodone formulations. PK Parameters: AUC0-t, AUC0-inf, Cmax, Residual Area, Tmax, T½ el, Kel, MRT, proportion of AUC before Tmax, AUC0-12 and AUC0-24</measure>
    <time_frame>Single-dose evaluation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety and tolerability of Egalet® hydrocodone formulations. Hematology, biochemistry, urinalysis, ECG, vital signs (including pulse oximetry), and adverse events monitoring.</measure>
    <time_frame>Single-dose evaluation</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Egalet® hydrocodone treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Egalet® hydrocodone Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Egalet® hydrocodone Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Egalet® hydrocodone Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single Dose Administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrocodone</intervention_name>
    <description>Extended Release tablet</description>
    <arm_group_label>Egalet® hydrocodone treatment A</arm_group_label>
    <arm_group_label>Egalet® hydrocodone Treatment B</arm_group_label>
    <arm_group_label>Egalet® hydrocodone Treatment C</arm_group_label>
    <arm_group_label>Egalet® hydrocodone Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrocodone &amp; acetaminophen combination</intervention_name>
    <description>Immediate Release tablet, hydrocodone and acetaminophen combination product</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smokers

          -  ≥18 and ≤55 years of age

          -  BMI ≥19 and ≤30.0

        Exclusion Criteria:

          -  Clinically significant abnormalities, physical or psychological illnesses or
             conditions contraindicating hydrocodone treatment

          -  History of significant abuse, dependance or addiction of alcohol, drugs or hard drugs
             within one year prior to screening

          -  Allergic to hydrocodone, hydromorphone, other opioids, or related drugs

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days
             prior to study drug administration

          -  Pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Andersen, M.Sc.Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Egalet A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2008</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hydrocodone</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety &amp; Tolerability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

